Abstract:Targeting polo-box domain (PBD) small molecule for polo-like kinase 1 (PLK1) inhibition is a viable alternative to target kinase domain (KD), which could avoid pan-selectivity and dose-limiting toxicity of ATP-competitive inhibitors. However, their efficacy in these settings is still low and inaccessible to clinical requirement. Herein, we utilized a structure-based high-throughput virtual screen to find novel chemical scaffold capable of inhibiting PLK1 via targeting PBD and identified an initial hit molecule compound 1a . Based on the lead compound 1a , a structural optimization approach was carried out and several series of derivatives with naphthalimide structural motif were synthesized. Compound 4Bb was identified as a new potent PLK1 inhibitor with a K D value of 0.29 μM. 4Bb could target PLK1 PBD to inhibit PLK1 activity and subsequently suppress the interaction of PLK1 with protein regulator of cytokinesis 1 (PRC1), finally leading to mitotic catastrophe in drug-resistant lung cancer cells. Furthermore, 4Bb could undergo nucleophilic substitution with the thiol group of glutathione (GSH) to disturb the redox homeostasis through exhausting GSH. By regulating cell cycle machinery and increasing cellular oxidative stress, 4Bb exhibited potent cytotoxicity to multiple cancer cells and drug-resistant cancer cells. Subcutaneous and oral administration of 4Bb could effectively inhibit the growth of drug-resistant tumors in vivo , doubling the survival time of tumor bearing mice without side effects in normal tissues. Thus, our study offers an orally-available, structurally-novel PLK1 inhibitor for drug-resistant lung cancer therapy.

Identification of A Novel Polo-Like Kinase 1 Inhibitor That Specifically Blocks the Functions of Polo-Box Domain

Discovery of Novel Polo-Like Kinase 1 Polo-Box Domain Inhibitors to Induce Mitotic Arrest in Tumor Cells.

Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1

Discovery of Non-ATP-Competitive Inhibitors of Polo-like Kinase 1.

Designed Inhibitor for Nuclear Localization Signal of Polo-Like Kinase 1 Induces Mitotic Arrest.

Identification of naphthalimide-derivatives as novel PBD-targeted polo-like kinase 1 inhibitors with efficacy in drug-resistant lung cancer cells

Dynamic and Multi-Pharmacophore Modeling for Designing Polo-Box Domain Inhibitors

Targeting Polo-like Kinase 1 by a Novel Pyrrole-Imidazole Polyamide–Hoechst Conjugate Suppresses Tumor Growth in Vivo

Identification of novel peptidomimetics targeting the polo-box domain of polo-like kinase 1

[Targeting the Substrate Binding Domain of Polo-Like Kinase 1: Advances in the Study of PBD1 Inhibitors].

Identification of Nitroimidazole-Oxime Derivatives Targeting the Polo-Box Domain of Polo-Like Kinase 1.

Inhibitors of the PLK1 polo-box domain: drug design strategies and therapeutic opportunities in cancer

Developments of Polo-like Kinase 1 (plk1) Inhibitors As Anti-Cancer Agents

Advance of Ser/Thr Kinase Polo-like Kinase 1(Plk1) Research

Design, synthesis and biological evaluation of phosphopeptides as Polo-like kinase 1 Polo-box domain inhibitors

Identification of Novel Polo-Like Kinase 1 Inhibitors by a Hybrid Virtual Screening.

Discovery of a Potent PLK1-PBD Small-Molecule Inhibitor As an Anticancer Drug Candidate Through Structure-Based Design

Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.

Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001

Plk1 As A Potential Drug Target in Cancer Therapy

Polo-like Kinase 1 Inhibitors in Human Cancer Therapy: Development and Therapeutic Potential